Search: onr:"swepub:oai:DiVA.org:uu-152761" >
The effect of the t...
The effect of the telomerase antagonist Imetelstat in esophageal carcinoma
-
- wu, xuping (author)
- Uppsala universitet,Enheten för onkologi
-
- Smavadati, Shirin (author)
- Uppsala universitet,Enheten för onkologi
-
- Nordfjäll, Katarina (author)
- Department of Medical Biosciences, pathology, Umeå University
-
show more...
-
- Karlsson, Krister (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
- Qvarnström, Fredrik (author)
- Uppsala universitet,Enheten för onkologi
-
- Simonsson, Martin (author)
- Uppsala universitet,Enheten för onkologi
-
- Bergquist, Michael (author)
- Uppsala universitet,Enheten för onkologi
-
- Gryaznov, Sergei (author)
- Geron Corporation, Menlo Park, CA, USA
-
- Ekman, Simon (author)
- Uppsala universitet,Enheten för onkologi
-
- Paulsson-Karlsson, Ylva (author)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi
-
show less...
-
(creator_code:org_t)
- English.
- Related links:
-
https://urn.kb.se/re...
Abstract
Subject headings
Close
- Telomerase is mainly active in human tumor cells, which provides an opportunity for a therapeutic window on telomerase targeting. We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, Imetelstat, as a drug candidate for treatment of esophageal cancer. Our results showed that Imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells. After only one week of Imetelstat treatment, a reduction of colony formation ability of esophageal cancer cells was observed. Furthermore, long-term treatment with Imetelstat decreased cell growth of esophageal cancer cells with different kinetics regarding telomere lengths. Cell cycle analysis demonstrated that short-term treatment with Imetelstat resulted in increased percentage of cells in G1 phase. Short-term Imetelstat treatment also increased γ-H2AX and 53BP1 foci staining in the esophageal cancer cell lines indicating a possible induction of DNA double strand breaks (DSBs). We also found that pre-treatment with Imetelstat led to increased number and size of 53BP1 foci after ionizing radiation. The increase of 53BP1 foci number was especially pronounced during the first 1 h of repair whereas the increase of foci size was prominent later on. This study supports the potential of Imetelstat as a therapeutic agent for the treatment of esophageal cancer.
Publication and Content Type
- vet (subject category)
- ovr (subject category)
To the university's database